MedTrace Logo

VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

NCT01891708 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2013-07-03

No results posted yet for this study

Summary

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Conditions

  • Non Small Cell Lung Cancer
  • Brain Metastasis

Interventions

OTHER

bevacizumab, standard chemotherapy and radiation

the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.

Sponsors & Collaborators

  • Li Liu

    lead OTHER

Principal Investigators

  • Li Liu, MD · Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01891708 on ClinicalTrials.gov